NCT06724055 is a clinical trial in Pancreatic Masses, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT06724055?

NCT06724055 is sponsored by Peking Union Medical College Hospital.

What condition does NCT06724055 study?

NCT06724055 studies Pancreatic Masses.

Is NCT06724055 still recruiting?

NCT06724055 is currently completed. Last updated 9 December 2024.

Last reviewed 2024-12-09 · How we verify

NCT06724055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Prediction of Pancreatic Masses

Completed Last updated 9 December 2024

What this trial tests

trial in Pancreatic Masses in 110 participants. Completed in 31 May 2023.

Timeline

1 January 2002

Primary endpoint
31 May 2023

31 May 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	110
Start date	1 January 2002
Primary completion	31 May 2023
Estimated completion	31 May 2023

Conditions studied

Pancreatic Masses — all drugs for Pancreatic Masses →

Sponsor

Peking Union Medical College Hospital

Who can join

Eligibility, any sex, with Pancreatic Masses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn if a strategy can be developed for differentiating autoimmune pancreatitis (AIP) and primary pancreatic lymphoma (PPL) from pancreatic ductal adenocarcinoma (PDAC) in patients presenting with pancreatic masses. The main question it aims to answer is: What features, in the perspectives of clinical manifestation, laboratory tests, and imaging, can differentiate different kinds of pancreatic masses (AIP, PPL and PDAC)? Participants will not be given any interventions since this is a retrospective observational study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06724055 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06724055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing